

GAV 1635

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX 520



Applicants: Dakai Liu et al.)
Serial No. 08/822,963)
Filed: March 21, 1997)
Title: VECTORS AND VIRAL VECTORS,
AND PACKAGING CELL LINES
FOR PROPAGATING SAME)

Group Art Unit: 1635

Examiner: Sean McGarry

16X
4/23

527 Madison Avenue, 9th Floor
New York, New York 10022
April 17, 1998

FILED BY EXPRESS MAIL

Honorable Commissioner
of Patents and Trademarks
Washington, D.C. 20231

RECEIVED

APR 22 1998

Attention: Box Sequence

U.S. POSTAL SERVICE
MAIL CENTER

**COMMUNICATION DIRECTED TO NOTICE
TO COMPLY WITH SEQUENCE RULES**

Dear Sirs:

This Communication is directed to the Notice To Comply With Sequence rules that was attached to the Notice to File Missing Parts of Application – Filing Date Granted that was mailed on July 14, 1997 in connection with the above-identified application and subsequent Communication dated March 19, 1998. A copy of the March 19, 1998 Communication with Notice To Comply With Requirements For Patent Application Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures is attached hereto.

In response to the sequence notice, Applicants hereby submit the following documents or items:

1. A copy of the March 19, 1998 Communication with Notice To Comply With Requirements For Patent Application Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures
2. initial paper copy of the "Sequence Listing;"

EXPRESS MAIL CERTIFICATE	
Express Mail Label No EM36656661US	
Deposit Date April 17, 1998	
I hereby certify that the paper and the attachments herein are being deposited with the United States Postal Service "Express Mail Post Office to Address" served under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington DC 20231	
Signature of Ronald C. Fedus	APRIL 17 1998
Reg. No. 32,567	Date

Dakai-Liu et al.

Serial No. 08/822,963

File: March 21, 1997

Page 2 (Communication Directed to Notice to Comply With Sequence Rules -
April 17, 1998)

3. Amendment directing entry of the "Sequence Listing into the specification;
4. computer readable form (CFR) copy of the "Sequence Listing;" and
5. Declaration Under 37 C.F.R. §1.821(g) attesting that the content of the paper and computer readable copies are the same and include no new matter.

No fee is believed due in connection with this Communication or the documents or items submitted herewith. If any fee or fees are due, however, the Patent and Trademark Office is hereby authorized to charge the amount of any such fee to Deposit Account 05-1135, or to credit any overpayment thereto.

If helpful to processing this Communication, the undersigned may be contacted by telephone at (212) 583-0100 during the daytime hours.

Respectfully submitted,

Ronald C. Fedus
Registration No. 32,567
Attorney for Applicants

ENZO THERAPEUTICS, INC.
c/o Enzo Biochem, Inc.
527 Madison Avenue (9th Fl.)
New York, New York 10022
(212) 583-0100